image
Supernus Pharmaceuticals, Inc. SUPN
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
Watchlist
$ 32.27
-1.44 %
$ 1.8 B
Market Cap
24.45
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SUPN stock under the worst case scenario is HIDDEN Compared to the current market price of 32.3 USD, Supernus Pharmaceuticals, Inc. is HIDDEN

SUPN Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SUPN stock under the base case scenario is HIDDEN Compared to the current market price of 32.3 USD, Supernus Pharmaceuticals, Inc. is HIDDEN

SUPN Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SUPN stock under the best case scenario is HIDDEN Compared to the current market price of 32.3 USD, Supernus Pharmaceuticals, Inc. is HIDDEN

SUPN Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart SUPN

image
1M 0%
6M -5%
1Y 10%
3Y 9%
5Y 78%
All
$40.0$40.0$39.0$39.0$38.0$38.0$37.0$37.0$36.0$36.0$35.0$35.0$34.0$34.0$33.0$33.0$32.0$32.0$31.0$31.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
662 M REVENUE
8.94%
Growth Rates
1Year 8.94%
3Years 4.51%
5Years 11.00%
7Years 11.85%
10Years 18.42%
81.7 M OPERATING INCOME
1649.93%
Growth Rates
1Year 1649.93%
3Years -1.72%
5Years -11.28%
7Years -2.79%
10Years 12.92%
73.9 M NET INCOME
5512.84%
Growth Rates
1Year 5512.84%
3Years 11.40%
5Years -8.16%
7Years 3.70%
10Years 14.03%
172 M OPERATING CASH FLOW
54.79%
Growth Rates
1Year 54.79%
3Years 10.59%
5Years 3.74%
7Years 5.96%
10Years 36.37%
-190 M INVESTING CASH FLOW
-70.65%
Growth Rates
1Year -70.65%
3Years -32.34%
5Years -3.75%
7Years -11.90%
10Years -44.19%
12.2 M FINANCING CASH FLOW
103.06%
Growth Rates
1Year 103.06%
3Years 27.93%
5Years 25.43%
7Years 11.53%
10Years 35.84%
174 M REVENUE
-0.87%
Growth Rates
1Year 8.94%
3Years 4.51%
5Years 11.00%
7Years 11.85%
10Years 18.42%
21.4 M OPERATING INCOME
-47.59%
Growth Rates
1Year 1649.93%
3Years -1.72%
5Years -11.28%
7Years -2.79%
10Years 12.92%
15.3 M NET INCOME
-60.18%
Growth Rates
1Year 5512.84%
3Years 11.40%
5Years -8.16%
7Years 3.70%
10Years 14.03%
44.4 M OPERATING CASH FLOW
-17.03%
Growth Rates
1Year 54.79%
3Years 10.59%
5Years 3.74%
7Years 5.96%
10Years 36.37%
-12.6 M INVESTING CASH FLOW
83.59%
Growth Rates
1Year -70.65%
3Years -32.34%
5Years -3.75%
7Years -11.90%
10Years -44.19%
5.89 M FINANCING CASH FLOW
91.54%
Growth Rates
1Year 103.06%
3Years 27.93%
5Years 25.43%
7Years 11.53%
10Years 35.84%
Balance Sheet Supernus Pharmaceuticals, Inc.
image
Current Assets 686 M
Cash & Short-Term Investments 454 M
Receivables 142 M
Other Current Assets 90.4 M
Non-Current Assets 682 M
Long-Term Investments 0
PP&E 11.5 M
Other Non-Current Assets 670 M
33.16 %10.39 %6.61 %49.01 %Total Assets$1.4b
Current Liabilities 292 M
Accounts Payable 4.59 M
Short-Term Debt 6.89 M
Other Current Liabilities 281 M
Non-Current Liabilities 39.9 M
Long-Term Debt 27.4 M
Other Non-Current Liabilities 12.6 M
84.53 %8.24 %3.78 %Total Liabilities$332.3m
EFFICIENCY
Earnings Waterfall Supernus Pharmaceuticals, Inc.
image
Revenue 662 M
Cost Of Revenue 77.9 M
Gross Profit 584 M
Operating Expenses 502 M
Operating Income 81.7 M
Other Expenses 7.8 M
Net Income 73.9 M
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00662m(78m)584m(502m)82m(8m)74mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
88.23% GROSS MARGIN
88.23%
Averages
1Year 88.23%
3Years 87.12%
5Years 87.67%
7Years 90.05%
10Years 91.39%
12.34% OPERATING MARGIN
12.34%
Averages
1Year 12.34%
3Years 7.19%
5Years 13.96%
7Years 20.42%
10Years 21.33%
11.16% NET MARGIN
11.16%
Averages
1Year 11.16%
3Years 6.83%
5Years 10.82%
7Years 15.72%
10Years 18.11%
7.13% ROE
7.13%
Averages
1Year 7.13%
3Years 4.71%
5Years 7.54%
7Years 11.60%
10Years 16.20%
5.40% ROA
5.40%
Averages
1Year 5.40%
3Years 3.02%
5Years 4.13%
7Years 5.97%
10Years 9.22%
5.69% ROIC
5.69%
Averages
1Year 5.69%
3Years 3.39%
5Years 5.00%
7Years 7.18%
10Years 12.60%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Supernus Pharmaceuticals, Inc.
image
180m180m160m160m140m140m120m120m100m100m80m80m60m60m40m40m20m20m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 73.9 M
Depreciation & Amortization 80.4 M
Capital Expenditures -725 K
Stock-Based Compensation 27.8 M
Change in Working Capital -2.05 M
Others 7.18 M
Free Cash Flow 171 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Supernus Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for SUPN of $38.7 , with forecasts ranging from a low of $36 to a high of $41 .
SUPN Lowest Price Target Wall Street Target
36 USD 11.56%
SUPN Average Price Target Wall Street Target
38.7 USD 19.82%
SUPN Highest Price Target Wall Street Target
41 USD 27.05%
Price
Max Price Target
Min Price Target
Average Price Target
4242404038383636343432323030282826262424May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Supernus Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
440 K USD 2
3-6 MONTHS
11.8 M USD 6
6-9 MONTHS
313 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
ATTENTION Supernus Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com - 2 weeks ago
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com - 2 weeks ago
ATTENTION Supernus Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com - 2 weeks ago
Supernus Pharmaceuticals, Inc. (SUPN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com - 2 weeks ago
SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Supernus Pharmaceuticals, Inc. Investment NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com - 2 weeks ago
An Investigation Has Commenced on Behalf of Supernus Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SUPN Losses. NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com - 3 weeks ago
SUPN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Supernus Pharmaceuticals, Inc. NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com - 3 weeks ago
ATTENTION SUPN SHAREHOLDERS: Investors who lost money on Supernus Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com - 3 weeks ago
Supernus Pharmaceuticals, Inc. (SUPN) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com - 3 weeks ago
Supernus Pharmaceuticals, Inc. Being Investigated on Behalf of Supernus Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details. NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com - 3 weeks ago
Supernus Pharmaceuticals, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Supernus Pharmaceuticals, Inc. (SUPN) NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com - 4 weeks ago
SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if You Lost Money on Your Supernus Pharmaceuticals, Inc. Investment NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo. accessnewswire.com - 1 month ago
8. Profile Summary

Supernus Pharmaceuticals, Inc. SUPN

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 1.8 B
Dividend Yield 0.00%
Description Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Contact 9715 Key West Avenue, Rockville, MD, 20850 https://www.supernus.com
IPO Date May 1, 2012
Employees 674
Officers Dr. Jonathan Rubin M.B.A., M.D. Senior Vice President of Research & Development and Chief Medical Officer Mr. Taylor Raiford Senior Vice President of Sales Mr. Jeff Bozick Senior Vice President of Supply Chain Dr. Bryan A. Roecklein Ph.D. Senior Vice President of Corporate Development Mr. Kevin T. Anderson Esq. Compliance Officer Mr. Jack A. Khattar M.B.A. Founder, President, Chief Executive Officer, Secretary & Director Mr. Frank Mottola Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs Dr. Todd Horich M.B.A., Ph.D. Senior Vice President of Marketing, Commercial Operations & Market Access Mr. Timothy C. Dec Senior Vice President & Chief Financial Officer Dr. Padmanabh P. Bhatt Ph.D. Chief Scientific Officer & Senior Vice President of Intellectual Property